{
  "title": "M21-1, Part VIII, Subpart iii, Chapter 4, Section C - Rating Claims for Disabilities Associated With Radiation Exposure",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177456/M21-1-Part-VIII-Subpart-iii-Chapter-4-Section-C-Rating-Claims-for-Disabilities-Associated-With-Radiation-Exposure",
  "content": "<-- Previous Section\nNext Section -->\nOverview\nIn This Section\nThis section contains the topic, “\nRating Claims for Disabilities Associated With Radiation Exposure\n.”\n1\n.\nRating Claims for Disabilities Associated With Radiation Exposure\nIntroduction\nThis topic contains information on rating claims for disabilities associated with radiation exposure, including\nprovisions of\nPublic Law (PL) 98-542\n, and\nPL 102-86\nhistory of time limits for disease manifestation for presumptive purposes under 38 CFR 3.309(d)\nlist of disabilities under 38 CFR 3.309(d) for which service connection (SC) is presumed\nlist of radiogenic disabilities under 38 CFR 3.311\n, and\nprovisions of\nPL 117-168\n.\nChange Date\nFebruary 28, 2024\nVIII.iii.4.C.1.a\n.\nProvisions of PL 98-542\nPublic Law (PL) 98-542\n, the\nVeterans' Dioxin and Radiation Exposure Compensation Standards Act\n, which was enacted on October 24, 1984, created several new provisions related to exposure to ionizing radiation.  These provisions included\nthe first recognition of specific disabilities presumptive to radiation exposure incurred during atmospheric nuclear testing in Hiroshima and Nagasaki, Japan, and\ncreation of the Veterans' Advisory Committee on Environmental Hazards.\nUnder the PL\n, the following claims that were denied\nprior\nto October 24, 1984, are entitled to a\nde novo\nreview:\nclaims for service connection (SC) based upon exposure to ionizing radiation as a consequence of service with the occupation forces of Hiroshima or Nagasaki, Japan, or\nclaims for SC based upon exposure to ionizing radiation in connection with nuclear testing.\nNotes\n:\nA\nde novo\nreview is a new and complete review of an issue with no deference given to the previous decision.\nThe submission of new and relevant evidence is\nnot\na prerequisite for readjudication of these claims.\nPL 98-542\nwas implemented through regulations on September 25, 1985, as historical 38 CFR 3.311b.\nReferences\n:  For more information on\nradiogenic disabilities under\n38 CFR 3.311\n, see\nM21-1, Part VIII, Subpart iii, 4.C.1.e\npresumptive disabilities under\n38 CFR 3.309(d)\n, see\nM21-1, Part VIII, Subpart iii, 4.C.1.d\n, and\ndeveloping claims under\n38 CFR 3.309(d)\n, see\nM21-1, Part VIII, Subpart iii, 4.A\n, and\n38 CFR 3.311\n, see\nM21-1, Part VIII, Subpart iii, 4.B\n.\nVIII.iii.4.C.1.b\n.\nProvisions of PL 102-86\nPL 102-86\n, the\nVeterans' Benefits Programs Improvement Act of 1991\n, effective August 14, 1991, extended eligibility to presumptive SC under\n38 CFR 3.309(d)\nto individuals engaged in a radiation-risk activity during\nactive duty for training, or\ninactive duty training.\nReference\n:  For more information on claims under\n38 CFR 3.309(d)\n, see\nM21-1, Part VIII, Subpart iii, 4.A\n.\nVIII.iii.4.C.1.c\n.\nHistory of Time Limits for Disease Manifestation for Presumptive Purposes Under 38 CFR 3.309(d)\nOriginally, in order to establish presumptive SC, the time limit for a disease listed under\n38 CFR 3.309(d)\nto become manifest to a degree of 10 percent or more was\n30 years for leukemia, and\n40 years for all other diseases.\nThe presumptive period was extended to 40 years for leukemia effective August 14, 1991.\nImportant\n:  Effective October 1, 1992, a time limit for manifestation is\nnot\nspecified or required for any disease listed under\n38 CFR 3.309(d)\n.\nReference\n:  For more information on time limits for manifestation of disabilities under\n38 CFR 3.311\n, see\n38 CFR 3.311(b)(5)\n.\nVIII.iii.4.C.1.d\n.\nList of Disabilities Under 38 CFR 3.309(d) for Which SC Is Presumed\nThe table below lists the disabilities for which SC is presumed based on a Veteran’s participation in a radiation-risk activity under\n38 CFR 3.309(d)\n.\nPL or Federal Register Citation\nPresumptive Disabilities Under 38 CFR 3.309(d)\nPL 100-321\neffective May 1, 1988\nCancer of the\nbile ducts\nbreast\nesophagus\ngallbladder\npancreas\npharynx\nsmall intestine\nstomach, and\nthyroid\nleukemia, other than chronic lymphocytic leukemia (CLL)\nlymphomas, except Hodgkin’s disease\nmultiple myeloma, and\nprimary liver cancer, except if cirrhosis or hepatitis B is indicated.\nPL 102-578\neffective October 1, 1992\nCancer of the\nsalivary gland, and\nurinary tract.\nNote\n:  The term\nurinary tract\nrefers to the\nkidneys\nrenal pelves\nureters\nurinary bladder, and\nurethra.\nPL 106-117\neffective November 30, 1999\nBronchiolo-alveolar carcinoma.\n67 FR 3612-3616\neffective March 26, 2002\nCancer of the\nbone\nbrain\ncolon\nlung, and\novary.\nReference\n:  For more information on developing claims under\n38 CFR 3.309(d)\n, see\nM21-1, Part VIII, Subpart iii, 4.A\n.\nVIII.iii.4.C.1.e\n.\nList of Radiogenic Disabilities Under 38 CFR 3.311\nThe table below lists the legislative history of radiogenic disabilities under\n38 CFR 3.311\n.\nPublic Law/Federal Register Citation\nRadiogenic Disabilities Listed Under 38 CFR 3.311\nPL 98-542\n, 50 FR 34459, effective August 26, 1985\nAll forms of leukemia except chronic lymphatic leukemia\ncancer of the\nthyroid\nfemale breast\nlung\nbone\nliver\nskin\nesophagus\nstomach\ncolon\npancreas\nkidney\nurinary bladder, and\nsalivary gland, and\nmultiple myeloma.\n54 FR 42803, effective October 18, 1989\nAll forms of leukemia except chronic lymphatic (lymphocytic) leukemia\nbreast cancer\nposterior subcapsular cataracts, and\nnon-malignant thyroid nodular disease.\n58 FR 16359, effective March 26, 1993\nOvarian cancer, and\nparathyroid adenoma.\n59 FR 45975, effective September 6, 1994\nTumors of the brain and central nervous system.\n60 FR 53277, effective October 13, 1995\nCancer of the rectum, and\nlymphomas other than Hodgkin’s disease.\n63 FR 50994, effective September 24, 1998\nProstate cancer, and\nany other cancer\nReference\n:  For more information on developing claims under\n38 CFR 3.311\n, see\nM21-1, Part VIII, Subpart iii, 4.B\n.\nVIII.iii.4.C.1.f\n.\nProvisions of PL 117-168\nEffective August 10, 2022,\nPL 117-168\n, Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act of 2022, or the Honoring our PACT Act of 2022, added new locations associated with radiation-risk activity as identified in\n38 CFR 3.309(d)(3)(ii)\n.\nThe Jackson Regional Office will undertake the required development to the Department of Defense to recognize radiation-risk activity for any Veteran who is shown to have participated in one of the qualifying activities during the applicable time frame as shown in the table below.\nActivity\nDates\nClean up of Enewetak Atoll\nJanuary 1, 1977, through December 31, 1980\nNuclear response near Palomares, Spain\nJanuary 17, 1966, to March 31, 1967\nNuclear response near Thule Air Force Base, Greenland\nJanuary 21, 1968, to September 25, 1968\nReference\n:  For more information on developing claims under\n38 CFR 3.309(d)\n, see\nM21-1, Part VIII, Subpart iii, 4.A\n.\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000177455\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 4, Section B - Developing Claims for Service Connection (SC) for Disabilities Resulting from Ionizing Radiation Exposure Under 38 CFR 3.311\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177455/M21-1-Part-VIII-Subpart-iii-Chapter-4-Section-B-Developing-Claims-for-Service-Connection-SC-for-Disabilities-Resulting-from-Ionizing-Radiation-Exposure-Under-38-CFR-3311\">&lt;-- Previous Section</a>  <a articleid=\"554400000177457\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 5, Section A - Developing Claims Based on Participation in Chemical Biological Radiological Nuclear and Explosives (CBRNE) Testing\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177457/M21-1-Part-VIII-Subpart-iii-Chapter-5-Section-A-Developing-Claims-Based-on-Participation-in-Chemical-Biological-Radiological-Nuclear-and-Explosives-CBRNE-Testing\">Next Section --&gt;</a></span></span></p><h2 class=\"ng-scope\"><a id=\"top\" name=\"top\"><strong><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></strong></a></h2><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <th scope=\"row\" style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In This Section</span></span></h3> </th> <td style=\"height: 8px; width: 15px; padding: 0px;\"></td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">This section contains the topic, “<a href=\"#1\" target=\"_self\">Rating Claims for Disabilities Associated With Radiation Exposure</a>.”</span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\"></p><h2 class=\"ng-scope\"><br/><strong><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">1<a id=\"1\" name=\"1\">.</a>  Rating Claims for Disabilities Associated With Radiation Exposure</span></span></strong> <br/> </h2><p class=\"ng-scope\"></p><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"></td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information on rating claims for disabilities associated with radiation exposure, including</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">provisions of</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#1a\" target=\"_self\"><em>Public Law (PL) 98-542</em></a>, and</span></span></div> </li> <li> <div><a href=\"#1b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>PL 102-86 </em></span></span></a></div> </li> </ul> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#1c\" target=\"_self\">history of time limits for disease manifestation for presumptive purposes under 38 CFR 3.309(d)</a></span></span></div> </li> <li> <div><a href=\"#1d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">list of disabilities under 38 CFR 3.309(d) for which service connection (SC) is presumed</span></span></a></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#1e\" target=\"_self\">list of radiogenic disabilities under 38 CFR 3.311</a>, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#1f\" target=\"_self\">provisions of <em>PL 117-168</em></a>.</span></span></div> </li> </ul> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <th scope=\"row\" style=\"width: 115px; text-align: left; padding: 0px;\"> <h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3> </th> <td style=\"height: 8px; width: 15px; padding: 0px;\"></td> <td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">February 28, 2024</span></span></td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.4.C.1.a<a id=\"1a\" name=\"1a\">.</a>  Provisions of PL 98-542</span></span></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"></td> <td style=\"width: 516px; padding: 0px;\"> <div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em>Public Law (PL) 98-542</em>, the <em>Veterans' Dioxin and Radiation Exposure Compensation Standards Act</em>, which was enacted on October 24, 1984, created several new provisions related to exposure to ionizing radiation.  These provisions included</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the first recognition of specific disabilities presumptive to radiation exposure incurred during atmospheric nuclear testing in Hiroshima and Nagasaki, Japan, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">creation of the Veterans' Advisory Committee on Environmental Hazards.</span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em>Under the PL</em>, the following claims that were denied <em>prior</em> to October 24, 1984, are entitled to a <em>de novo</em> review:</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">claims for service connection (SC) based upon exposure to ionizing radiation as a consequence of service with the occupation forces of Hiroshima or Nagasaki, Japan, or</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">claims for SC based upon exposure to ionizing radiation in connection with nuclear testing.</span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>:</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">A <em>de novo </em>review is a new and complete review of an issue with no deference given to the previous decision.</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The submission of new and relevant evidence is <strong><em>not</em></strong> a prerequisite for readjudication of these claims.</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em>PL 98-542</em> was implemented through regulations on September 25, 1985, as historical 38 CFR 3.311b.</span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">radiogenic disabilities under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1311&amp;rgn=div8\" target=\"_blank\">38 CFR 3.311</a>, see <a href=\"#1e\" target=\"_self\">M21-1, Part VIII, Subpart iii, 4.C.1.e</a></span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">presumptive disabilities under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(d)</a>, see <a href=\"#1d\" target=\"_self\">M21-1, Part VIII, Subpart iii, 4.C.1.d</a>, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">developing claims under</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(d)</a>, see <a articleid=\"554400000177454\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 4, Section A - Developing Claims for Service Connection (SC) for Disabilities Resulting from Ionizing Radiation Exposure Under 38 CFR 3.309\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177454/M21-1-Part-VIII-Subpart-iii-Chapter-4-Section-A-Developing-Claims-for-Service-Connection-SC-for-Disabilities-Resulting-from-Ionizing-Radiation-Exposure-Under-38-CFR-3309\">M21-1, Part VIII, Subpart iii, 4.A</a>, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1311&amp;rgn=div8\" target=\"_blank\">38 CFR 3.311</a>, see <a articleid=\"554400000177455\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 4, Section B - Developing Claims for Service Connection (SC) for Disabilities Resulting from Ionizing Radiation Exposure Under 38 CFR 3.311\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177455/M21-1-Part-VIII-Subpart-iii-Chapter-4-Section-B-Developing-Claims-for-Service-Connection-SC-for-Disabilities-Resulting-from-Ionizing-Radiation-Exposure-Under-38-CFR-3311\">M21-1, Part VIII, Subpart iii, 4.B</a>.</span></span></div> </li> </ul> </li> </ul> </div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.4.C.1.b<a id=\"1b\" name=\"1b\">.</a>  Provisions of PL 102-86</span></span></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"></td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em>PL 102-86</em>, the <em>Veterans' Benefits Programs Improvement Act of 1991</em>, effective August 14, 1991, extended eligibility to presumptive SC under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(d)</a> to individuals engaged in a radiation-risk activity during</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">active duty for training, or </span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">inactive duty training.</span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on claims under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(d)</a>, see  <a articleid=\"554400000177454\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 4, Section A - Developing Claims for Service Connection (SC) for Disabilities Resulting from Ionizing Radiation Exposure Under 38 CFR 3.309\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177454/M21-1-Part-VIII-Subpart-iii-Chapter-4-Section-A-Developing-Claims-for-Service-Connection-SC-for-Disabilities-Resulting-from-Ionizing-Radiation-Exposure-Under-38-CFR-3309\">M21-1, Part VIII, Subpart iii, 4.A</a>.</span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.4.C.1.c<a id=\"1c\" name=\"1c\">.</a>  History of Time Limits for Disease Manifestation for Presumptive Purposes Under 38 CFR 3.309(d)</span></span></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"></td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Originally, in order to establish presumptive SC, the time limit for a disease listed under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(d)</a> to become manifest to a degree of 10 percent or more was</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">30 years for leukemia, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">40 years for all other diseases.</span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The presumptive period was extended to 40 years for leukemia effective August 14, 1991.</span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em><strong>Important</strong></em>:  Effective October 1, 1992, a time limit for manifestation is <em>not</em> specified or required for any disease listed under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(d)</a>.</span></span></div> <div></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on time limits for manifestation of disabilities under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1311&amp;rgn=div8\" target=\"_blank\">38 CFR 3.311</a>, see <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1311&amp;rgn=div8\" target=\"_blank\">38 CFR 3.311(b)(5)</a>.</span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.4.C.1.d<a id=\"1d\" name=\"1d\">.</a>  List of Disabilities Under 38 CFR 3.309(d) for Which SC Is Presumed</span></span></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"></td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The table below lists the disabilities for which SC is presumed based on a Veteran’s participation in a radiation-risk activity under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(d)</a>.</span></span></div> <div></div> <table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 493px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is a PL/federal register citation-presumptive disabilities under 38 CFR 3.309(d) table.  Column 1 lists the PL or federal register citation, and column 2 contains the presumptives disabilities under 38 CFR 3.309(d).\"> <thead> <tr> <th scope=\"col\" style=\"width: 107px; padding: 1px;\"> <div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>PL or Federal Register Citation</strong></span></span></div> </th> <th scope=\"col\" style=\"width: 396px; padding: 1px;\"> <div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Presumptive Disabilities Under 38 CFR 3.309(d) </strong></span></span></div> </th> </tr> </thead> <tbody> <tr> <td style=\"width: 107px; vertical-align: top; padding: 1px;\"> <div align=\"left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>PL 100-321</em> effective May 1, 1988</span></span></div> </td> <td style=\"width: 396px; padding: 1px;\"> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Cancer of the</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">bile ducts</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">breast</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">esophagus</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">gallbladder</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">pancreas</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">pharynx</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">small intestine</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">stomach, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">thyroid</span></span></div> </li> </ul> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">leukemia, other than chronic lymphocytic leukemia (CLL)</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">lymphomas, except Hodgkin’s disease</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">multiple myeloma, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">primary liver cancer, except if cirrhosis or hepatitis B is indicated.</span></span></div> </li> </ul> </td> </tr> <tr> <td style=\"width: 107px; vertical-align: top; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>PL 102-578</em> effective October 1, 1992</span></span></div> </td> <td style=\"width: 396px; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Cancer of the</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">salivary gland, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">urinary tract.</span></span></div> </li> </ul> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Note</em></strong>:  The term <strong><em>urinary tract</em></strong> refers to the</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">kidneys</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">renal pelves</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">ureters</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">urinary bladder, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">urethra.</span></span></div> </li> </ul> </td> </tr> <tr> <td style=\"width: 107px; vertical-align: top; padding: 1px;\"> <p><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em>PL 106-117</em> effective November 30, 1999</span></span></p> </td> <td style=\"width: 396px; padding: 1px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Bronchiolo-alveolar carcinoma.</span></span></td> </tr> <tr> <td style=\"width: 107px; vertical-align: top; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em>67 FR 3612-3616 </em></span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">effective March 26, 2002</span></span></div> </td> <td style=\"width: 396px; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Cancer of the</span></span></div> <ul> <li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">bone</span></span></li> <li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">brain</span></span></li> <li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">colon</span></span></li> <li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">lung, and</span></span></li> <li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">ovary.</span></span></li> </ul> </td> </tr> </tbody> </table> <div></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on developing claims under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(d)</a>, see <a articleid=\"554400000177454\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 4, Section A - Developing Claims for Service Connection (SC) for Disabilities Resulting from Ionizing Radiation Exposure Under 38 CFR 3.309\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177454/M21-1-Part-VIII-Subpart-iii-Chapter-4-Section-A-Developing-Claims-for-Service-Connection-SC-for-Disabilities-Resulting-from-Ionizing-Radiation-Exposure-Under-38-CFR-3309\">M21-1, Part VIII, Subpart iii, 4.A</a>.</span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.4.C.1.e<a id=\"1e\" name=\"1e\">.</a>  List of Radiogenic Disabilities Under 38 CFR 3.311</span></span></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"></td> <td style=\"width: 516px; padding: 0px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The table below lists the legislative history of radiogenic disabilities under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=dd5c2a3a4d6377c0b256d722aeba0f25&amp;node=se38.1.3_1311&amp;rgn=div8\" target=\"_blank\">38 CFR 3.311</a>.</span></span></div> <div></div> <table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is a PL/Federal Register Citation-Presumptive Disabilities table.  Column 1 contains the PL or Federal Register Citation and column 2 contains the presumptive disabilities under 38 CFR 3.311.\" width=\"510\"> <thead> <tr> <th scope=\"col\" style=\"width: 106px; padding: 1px;\"> <div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Public Law/Federal Register Citation</strong></span></span></div> </th> <th scope=\"col\" style=\"width: 404px; padding: 1px;\"> <div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Radiogenic Disabilities Listed Under 38 CFR 3.311</strong></span></span></div> </th> </tr> </thead> <tbody> <tr> <td style=\"width: 106px; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em>PL 98-542</em>, 50 FR 34459, effective August 26, 1985</span></span></div> </td> <td style=\"width: 404px; padding: 1px;\"> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">All forms of leukemia except chronic lymphatic leukemia</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">cancer of the</span></span></div> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">thyroid</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">female breast</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">lung</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">bone</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">liver</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">skin</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">esophagus</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">stomach</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">colon</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">pancreas</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">kidney</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">urinary bladder, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">salivary gland, and</span></span></div> </li> </ul> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">multiple myeloma.</span></span></div> </li> </ul> </td> </tr> <tr> <td style=\"width: 106px; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">54 FR 42803, effective October 18, 1989</span></span></div> </td> <td style=\"width: 404px; padding: 1px;\"> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">All forms of leukemia except chronic lymphatic (lymphocytic) leukemia</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">breast cancer</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">posterior subcapsular cataracts, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">non-malignant thyroid nodular disease.</span></span></div> </li> </ul> </td> </tr> <tr> <td style=\"width: 106px; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">58 FR 16359, effective March 26, 1993</span></span></div> </td> <td style=\"width: 404px; padding: 1px;\"> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Ovarian cancer, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">parathyroid adenoma.</span></span></div> </li> </ul> </td> </tr> <tr> <td style=\"width: 106px; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">59 FR 45975, effective September 6, 1994</span></span></div> </td> <td style=\"width: 404px; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Tumors of the brain and central nervous system.</span></span></div> </td> </tr> <tr> <td style=\"width: 106px; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">60 FR 53277, effective October 13, 1995</span></span></div> </td> <td style=\"width: 404px; padding: 1px;\"> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Cancer of the rectum, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">lymphomas other than Hodgkin’s disease.</span></span></div> </li> </ul> </td> </tr> <tr> <td style=\"width: 106px; padding: 1px;\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">63 FR 50994, effective September 24, 1998</span></span></div> </td> <td style=\"width: 404px; padding: 1px;\"> <ul> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Prostate cancer, and</span></span></div> </li> <li> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">any other cancer</span></span></div> </li> </ul> </td> </tr> </tbody> </table> <div></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on developing claims under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1311&amp;rgn=div8\" target=\"_blank\">38 CFR 3.311</a>, see <a articleid=\"554400000177455\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 4, Section B - Developing Claims for Service Connection (SC) for Disabilities Resulting from Ionizing Radiation Exposure Under 38 CFR 3.311\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177455/M21-1-Part-VIII-Subpart-iii-Chapter-4-Section-B-Developing-Claims-for-Service-Connection-SC-for-Disabilities-Resulting-from-Ionizing-Radiation-Exposure-Under-38-CFR-3311\">M21-1, Part VIII, Subpart iii, 4.B</a>.</span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"> <tbody> <tr> <td style=\"width: 115px; vertical-align: top; padding: 0px;\"> <h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.4.C.1.f<a id=\"1f\" name=\"1f\">.</a>  Provisions of PL 117-168</span></span></h3> </td> <td style=\"height: 8px; width: 15px; padding: 0px;\"></td> <td style=\"width: 516px; padding: 0px;\"> <div> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Effective August 10, 2022, <i>PL 117-168</i>, Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act of 2022, or the Honoring our PACT Act of 2022, added new locations associated with radiation-risk activity as identified in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=85bf12b768c222d2a3b78b9c85031c0b&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(d)(3)(ii)</a>.</span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"color: black\">The Jackson Regional Office will undertake the required development to the Department of Defense to recognize radiation-risk activity for any Veteran who is shown to have participated in one of the qualifying activities during the applicable time frame as shown in the table below.</span></span></span></div> <div></div> <table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width: 510px; border-spacing: 1px; border-collapse: revert;\" summary=\"This is a two column table.  Column 1 lists the activity and column 2 lists the dates. \" width=\"510\"> <thead> <tr> <th style=\"padding: 1px;\" valign=\"top\"> <div align=\"center\" style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b>Activity</b></span></span></div> </th> <th style=\"padding: 1px;\" valign=\"top\"> <div align=\"center\" style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b>Dates</b></span></span></div> </th> </tr> </thead> <tbody> <tr> <td style=\"padding: 1px;\" valign=\"top\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Clean up of Enewetak Atoll</span></span></div> </td> <td style=\"padding: 1px;\" valign=\"top\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">January 1, 1977, through December 31, 1980</span></span></div> </td> </tr> <tr> <td style=\"padding: 1px;\" valign=\"top\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Nuclear response near Palomares, Spain</span></span></div> </td> <td style=\"padding: 1px;\" valign=\"top\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">January 17, 1966, to March 31, 1967</span></span></div> </td> </tr> <tr> <td style=\"padding: 1px;\" valign=\"top\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Nuclear response near Thule Air Force Base, Greenland</span></span></div> </td> <td style=\"padding: 1px;\" valign=\"top\"> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">January 21, 1968, to September 25, 1968</span></span></div> </td> </tr> </tbody> </table> <div></div> </div> <div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on developing claims under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(d)</a>, see <a articleid=\"554400000177454\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 4, Section A - Developing Claims for Service Connection (SC) for Disabilities Resulting from Ionizing Radiation Exposure Under 38 CFR 3.309\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177454/M21-1-Part-VIII-Subpart-iii-Chapter-4-Section-A-Developing-Claims-for-Service-Connection-SC-for-Disabilities-Resulting-from-Ionizing-Radiation-Exposure-Under-38-CFR-3309\">M21-1, Part VIII, Subpart iii, 4.A</a>.</span></span></div> </td> </tr> </tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\" style=\"text-align: right\"> <span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000177455\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 4, Section B - Developing Claims for Service Connection (SC) for Disabilities Resulting from Ionizing Radiation Exposure Under 38 CFR 3.311\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177455/M21-1-Part-VIII-Subpart-iii-Chapter-4-Section-B-Developing-Claims-for-Service-Connection-SC-for-Disabilities-Resulting-from-Ionizing-Radiation-Exposure-Under-38-CFR-3311\">&lt;-- Previous Section</a>  <a articleid=\"554400000177457\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 5, Section A - Developing Claims Based on Participation in Chemical Biological Radiological Nuclear and Explosives (CBRNE) Testing\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177457/M21-1-Part-VIII-Subpart-iii-Chapter-5-Section-A-Developing-Claims-Based-on-Participation-in-Chemical-Biological-Radiological-Nuclear-and-Explosives-CBRNE-Testing\">Next Section --&gt;</a></span></span></p><p class=\"ng-scope\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&node=se38.1.3_1309&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=85bf12b768c222d2a3b78b9c85031c0b&node=se38.1.3_1309&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=dd5c2a3a4d6377c0b256d722aeba0f25&node=se38.1.3_1311&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&node=se38.1.3_1311&rgn=div8"
  ],
  "scraped_at": "2025-06-16T22:58:37.164149",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177457/M21-1-Part-VIII-Subpart-iii-Chapter-5-Section-A-Developing-Claims-Based-on-Participation-in-Chemical-Biological-Radiological-Nuclear-and-Explosives-CBRNE-Testing"
}